Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173325 · ClinicalTrials.gov registry record · Phase 1
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
A Phase 1 study, sponsored by Augusta University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04173325 is a Phase 1 study that was terminated before completion, run by Augusta University. The registered enrollment target is 10 participants.
The verdict
NCT04173325, a Phase 1 study, was terminated before completion, sponsored by Augusta University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.
Interventions
- DRUG Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
- DRUG Irinotecan Injection [Camptosar]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173325
The ClinicalTrials.gov registry entry for NCT04173325 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] is the first listed.
NCT04173325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04173325 about?
NCT04173325 is a clinical study titled "Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer". This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together a...
What is the current status of trial NCT04173325?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-01-06. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT04173325?
The interventions under investigation include: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG), Irinotecan Injection [Camptosar] (DRUG).
Who is sponsoring clinical trial NCT04173325?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.